Nucleus Genomics announces $14 million in new funding to scale software-first health care

Five years after founding Nucleus in my bedroom, I’m thrilled to share that we've raised a $14 million Series A, bringing our total backing to $32 million.The new financing accelerates our ability to run a software playbook — one that’s scalable, accessible, and user-first — in healthcare, a legacy industry that’s resisted change for decades.

Our current roadmap is ambitious, including dramatically expanding our genetic risk assessments and adding features to help users plan healthy families. We have an exceptionally strong team to execute it, with the support of some of the sharpest investors in tech today.

In the coming years, Nucleus will transform a health care system that’s gridlocked Americans in second opinions, red tape, and dated treatments. We’re going to make preventable diseases a thing of the past. I’m beyond proud of the movement our team has built so far:

• In the last three months, we’ve averaged 68% month-over-month revenue growth.

• Since November, our monthly users have tripled. Almost every single Nucleus customer discovers a previously invisible genetic risk.

• Less than a year after going live, we’ve scaled up from 10 genetic analyses to over 800.

None of our growth would be possible without passionate customers, providers, investors — and our incredible team.

To that end, I’m thrilled to announce that Matt Lanter, former co-founder of OpenStore, chief of staff at Founders Fund, and longtime Nucleus investor, is joining as President. His decades of experience helping scale billion-dollar companies will be a tremendous addition to an already deeply talented team.

I’m also excited to announce Nucleus has acquired Cambrean, an AI-based health platform pioneering algorithms to transform data from wearables like Oura rings and Apple Watches into actionable recommendations. We’re excited to welcome the founder, David Sloane, to our product team, where he’ll spearhead wider data integrations.

Finally, we’re grateful to our early clinical partners, including Bionic Health, for pioneering genetic medicine in the clinic to better inform patient care. This partnership is the first of many for Nucleus. Our mission is to bring clinical-grade genetic insights that transform one’s healthcare to everyone. The most innovative clinics in the country are layering in whole-genome sequencing into their standard of care to do just that.

It’s been a privilege to work with the best firms and individual investors across consumer, healthcare, and deep tech. We are honored to continue to partner with Seven Seven Six and Founders Fund in this round of financing, as well as are excited to welcome a slew of new investors including Neo, One Eight Capital, Giant Step, Common Metal, Asylum Ventures, Rose Street Capital, Balaji Srinivasan, Amanda Bradford and many others to our cap table.

Nucleus has already translated atoms to bits, and this new capital gives us the ability to increase our value to customers more quickly. Our roadmap includes the launch of family planning features — including analyzing the risk of someone passing down over 800 diseases to their children —  and genetic analyses for how customers metabolize medications and supplements. Additionally, we will dramatically expand our consumer AI health tools — our most in-demand feature — to help users take action on their results more easily.

Each of these features brings us closer to making preventable diseases a thing of the past. If you would like to order Nucleus for yourself, check us out here, or gift it to a loved one here.